Novo Announces Phase 3 Results in Children Aged 6 to Under 12
Weight Loss Effect Confirmed for First Time in Growing Children
Repeated Criticism in South Korea Over Prescriptions to Children

Novo Nordisk's obesity treatment Wegovy lowered the body mass index (BMI) of children with obesity aged 6 to under 12 by 13.5% after 68 weeks. Wegovy is currently approved for use only in people aged 12 and older, both in South Korea and abroad. The findings provide a basis for expanding its use to children of elementary school age.


According to the results of a Phase 3 clinical trial published on November 16 local time in the New England Journal of Medicine (NEJM), the average BMI of children who received Wegovy fell by 13.5% after 68 weeks. Over the same period, BMI in the placebo group rose by 2.7%. The trial included 167 children with obesity aged 6 to under 12, more than 85% of whom had Class II or III obesity. The findings were also presented at ObesityWeek 2026, an academic conference on obesity held in Washington, DC, from November 14 to 17.


Image depicting childhood obesity. AI-generated image.

Image depicting childhood obesity. AI-generated image.

View original image

The treatment's effectiveness declined in its second year. At week 104, BMI in the treatment group had fallen by 9.4%, a smaller decrease than at week 68. At the same point, BMI in the placebo group had risen by 8.4%.


Adverse events occurred in 96% of the treatment group and 93% of the placebo group. Gastrointestinal adverse events, such as nausea and vomiting, were the most common. One child in the treatment group stopped treatment for this reason. Novo Nordisk said, "No safety concerns related to growth or pubertal development were identified."


In the United States, Wegovy is approved for chronic weight management in adults and adolescents aged 12 and older. Its use in children under 12 has not been approved. The trial appears to have been conducted with an application to expand the drug's pediatric indication in mind.


Wegovy's approved age threshold has remained at 12 because children's bodies begin to more closely resemble adults' around that age. When puberty starts around age 12, children's bodies grow, and their ability to break down and eliminate drugs approaches adult levels. This makes it easier to predict the effects and side effects of using the adult dose. South Korea's approval condition requiring a body weight of more than 60 kg is also based on the need for a body size that can accommodate the adult dose of 2.4 mg.


There have also been significant concerns that, in children under 12, appetite-suppressing drugs could reduce the intake of nutrients needed during a period of rapid growth. The American Academy of Pediatrics (AAP) likewise recommended in its 2023 clinical practice guideline that pharmacological treatment be considered for adolescents aged 12 and older with obesity.


Repeated Concerns in South Korea Over Prescriptions for Children Under 12


Wegovy has been available for use in adolescents in South Korea since October 2025. It may be used by adolescents aged 12 and older whose initial BMI is at least 30 under adult criteria and who weigh more than 60 kg. Before approval, the Central Pharmaceutical Affairs Council recognized the validity of adding the adolescent indication but called for monitoring, including post-marketing surveillance. After approval, the Ministry of Food and Drug Safety said that clinical trials had found higher rates of cholelithiasis, cholecystitis, and hypotension among adolescents aged 12 and older than among adults, and advised that the drug be used only for treatment.


Prescriptions outside the approved age range have been raised as an issue at every parliamentary audit. At last year's audit, Kim Namhee, a lawmaker from the Democratic Party of Korea, said that Wegovy had been prescribed 69 times to children under 12 between its launch in South Korea in October 2024 and August 2025. Fellow party lawmaker So Byeonghun pointed out that 2,604 cases of Wegovy prescriptions to minors had been reviewed.



The number of prescriptions was even higher at this year's parliamentary audit. At the Ministry of Food and Drug Safety audit last month, Seo Youngseok, a lawmaker from the Democratic Party of Korea, said that more than 12,000 teenagers had been prescribed Wegovy or Mounjaro, and that 28 cases involved children under 10.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing